Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

What To Know: Under the agreement, all strengths of the medications will now be available to eligible self-paying patients at $499 per month through GoodRx's platform.

Health Canada has approved Ozempic to reduce the risk of further kidney decline among patients with Type 2 diabetes, which has raised questions.

Eli Lilly and Novo Nordisk are expected to price their new obesity pills in line with existing injections, as analysts cite ...

Viking Therapeutics stock tumbled after the drugmaker released study results of its experimental weight-loss pill.

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes ...

Although the FDA has since removed these drugs from its shortage list, stakeholders say compounded drugs continue to be sold.

Viking Therapeutics' stock crashed 40% in early trading on Tuesday after a phase 2 trial of its weight-loss pill showed a ...

The American Diabetes Association Scientific Sessions, held in June, featured cutting-edge science, from new agents to treat ...

Weight loss before pregnancy linked to lower rates of gestational diabetes and C-sections. Experts discuss implications, limitations, and how to counsel patients.

Novo Nordisk announced Monday that U.S. patients can now get a month's supply of Ozempic, the blockbuster diabetes drug, for ...